Accrued Expenses (Details) - Schedule of accrued expenses - USD ($) |
3 Months Ended | 12 Months Ended |
---|---|---|
Mar. 31, 2021 |
Dec. 31, 2020 |
|
Schedule of accrued expenses [Abstract] | ||
Consulting fees | $ 1,391,923 | $ 1,718,559 |
Professional fees | 658,069 | 1,261,751 |
Employee and director compensation | 582,878 | 878,292 |
Research and development fees | 134,072 | 17,817 |
Interest | 104,434 | 184,576 |
Patent costs | 8,974 | |
Travel expenses | 4,600 | 4,600 |
Other | 45,321 | |
Total | $ 2,884,950 | $ 4,110,916 |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Employee and director compensation. No definition available.
|
X | ||||||||||
- Definition Costs incurred in connection with filing and prosecuting patent applications. No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. No definition available.
|
X | ||||||||||
- Definition Expenses incurred for travel and entertainment during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|